Beximco has seen a healthy financial first half on the back of 20 new product launches, in 29 presentation forms and strengths, including the introduction of six products for the first time in Bangladesh.
[Sidebar#GB151382]
Beximco Grows With 20 Launches In Financial First Half
As Bangladeshi Company Reports Double-Digit Growth Domestically And Overall
Listen to this article
Bangladesh-based Beximco has delivered double-digit growth in its financial first half ended 31 December 2021, on the back of 20 new product launches domestically and expanding into new markets internationally.
Stay ahead of every shift in generics and biosimilars.
More from Earnings
• By
Video provides a powerful way to help you prove your point. When you click Online Video, you can paste in the embed code for the video you want to add. You can also type a keyword to search online for the video that best fits your document.
• By
We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.
• By
We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.
More from Business
• By
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
• By
A look at new research on the cardiovascular effects of ADHD medications and what it means for clinical care. This article explores the latest clinical and epidemiological research on the cardiovascular effects of medications commonly prescribed for ADHD, examining potential heart-related risks, underlying mechanisms, and their implications for patient safety, clinical decision-making, and long-term treatment strategies across diverse age groups and risk profiles.